151
Views
4
CrossRef citations to date
0
Altmetric
Drug Profile

Eltrombopag for the treatment of idiopathic thrombocytopenic purpura

Pages 145-152 | Published online: 10 Jan 2014

References

  • George JN, Woolf SH, Raskob GE et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood88(1), 3–40 (1996).
  • Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch. Intern. Med.160(11), 1630–1638 (2000).
  • Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood97(9), 2549–2554 (2001).
  • Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin. Proc.79(4), 504–522 (2004).
  • Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood106(7), 2244–2251 (2005).
  • George JN. Management of patients with refractory immune thrombocytopenic purpura. J. Thromb. Haemost.4(8), 1664–1672 (2006).
  • Bussel J. Treatment of immune thrombocytopenic purpura in adults. Semin. Hematol.43(3 Suppl. 5), S3–S10 (2006).
  • Stasi R, Stipa E, Masi M et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am. J. Med.98(5), 436–442 (1995).
  • Cheng Y, Wong RS, Soo YO et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N. Engl. J. Med.349(9), 831–836 (2003).
  • Mazzucconi MG, Fazi P, Bernasconi S et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood109(4), 1401–1407 (2007).
  • Scaradavou A, Woo B, Woloski BM et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood89(8), 2689–2700 (1997).
  • Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood104(9), 2623–2634 (2004).
  • Arnold DM, Dentali F, Crowther MA et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann. Intern. Med.146(1), 25–33 (2007).
  • Gernsheimer T. Epidemiology and pathophysiology of immune thrombocytopenic purpura. Eur. J. Haematol. Suppl. (69), 3–8 (2008).
  • Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br. J. Haematol.122(6), 966–974 (2003).
  • Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J. Thromb. Haemost.4(11), 2377–2383 (2006).
  • Ruggeri M, Fortuna S, Rodeghiero F. Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature. Haematologica93(1), 98–103 (2008).
  • Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb. Haemost.99(1), 4–13 (2008).
  • Kuter DJ, Bussel JB, Lyons RM et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet371(9610), 395–403 (2008).
  • Kaushansky K. Thrombopoietin: accumulating evidence for an important biological effect on the hematopoietic stem cell. Ann. NY Acad. Sci.996, 39–43 (2003).
  • Geddis AE, Linden HM, Kaushansky K. Thrombopoietin: a pan-hematopoietic cytokine. Cytokine Growth Factor Rev.13(1), 61–73 (2002).
  • Sungaran R, Markovic B, Chong BH. Localization and regulation of thrombopoietin mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood89(1), 101–107 (1997).
  • Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood86(2), 419–431 (1995).
  • Fielder PJ, Gurney AL, Stefanich E et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood87(6), 2154–2161 (1996).
  • Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br. J. Haematol.106(2), 345–356 (1999).
  • Kaushansky K, Drachman JG. The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. Oncogene21(21), 3359–3367 (2002).
  • Siegel RS, Rae JL, Barth S et al. Platelet survival and turnover: important factors in predicting response to splenectomy in immune thrombocytopenic purpura. Am. J. Hematol.30(4), 206–212 (1989).
  • Louwes H, Zeinali Lathori OA, Vellenga E, de Wolf JT. Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura. Am. J. Med.106(4), 430–434 (1999).
  • Hoffman R, Zaknoen S, Yang HH et al. An antibody cytotoxic to megakaryocyte progenitor cells in a patient with immune thrombocytopenic purpura. N. Engl. J. Med.312(18), 1170–1174 (1985).
  • Chang M, Nakagawa PA, Williams SA et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood102(3), 887–895 (2003).
  • Takahashi R, Sekine N, Nakatake T. Influence of monoclonal antiplatelet glycoprotein antibodies on in vitro human megakaryocyte colony formation and proplatelet formation. Blood93(6), 1951–1958 (1999).
  • Chang M, Qian JX, Lee SM et al. Tissue uptake of circulating thrombopoietin is increased in immune-mediated compared with irradiated thrombocytopenic mice. Blood93(8), 2515–2524 (1999).
  • Kosugi S, Kurata Y, Tomiyama Y et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br. J. Haematol.93(3), 704–706 (1996).
  • Porcelijn L, Folman CC, Bossers B et al. The diagnostic value of thrombopoietin level measurements in thrombocytopenia. Thromb. Haemost.79(6), 1101–1105 (1998).
  • Kuter DJ. New thrombopoietic growth factors. Blood109(11), 4607–4616 (2007).
  • Li J, Yang C, Xia Y et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood98(12), 3241–3248 (2001).
  • Kaushansky K. Hematopoietic growth factor mimetics. Ann. NY Acad. Sci.938, 131–138 (2001).
  • Evangelista ML, Amadori S, Stasi R. Biologic aspects of thrombopoietin and the development of novel thrombopoietic agents for clinical use. Curr. Drug Discov. Technol.4(3), 162–173 (2007).
  • Erickson-Miller CL, DeLorme E, Tian SS et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp. Hematol.33(1), 85–93 (2005).
  • Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs68(7), 901–912 (2008).
  • Erickson-Miller CL, DeLorme E, Iskander M et al. Species specificity and receptor domain interaction of a small molecule TPO receptor agonist. Blood104 (2004) (Abstract 2909).
  • Jenkins JM, Williams D, Deng Y et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood109(11), 4739–4741 (2007).
  • Erhardt J, Erickson-Miller CL, Tapley P. SB 497115-GR, a low molecular weight TPOR agonist, does not induce platelet activation or enhance agonist-induced platelet aggregation in vitro. Blood104 (2004) (Abstract 3888).
  • Bussel JB, Cheng G, Saleh MN et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N. Engl. J. Med.357(22), 2237–2247 (2007).
  • Bussel J, Provan A, Shamsi T et al. Eltrombopag raises platelet count and reduces bleeding compared with placebo during short-term treatment in chronic idiopathic thrombocytopenic purpura: a Phase III study. Haematologica92(Suppl. 1) (2007) (Abstract 0390).
  • Bussel JB, Cheng G, Saleh M et al. Long-term safety and efficacy of oral eltrombopag for the treatment of idiopathic thrombocytopenic purpura (ITP). Haematologica93(Suppl. 1) (2008) (Abstract 0949).
  • Psaila B, Bussel JB, Vasey S et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic ITP. Haematologica93(Suppl. 1) (2008) (Abstract 0294).
  • Ulich TR, del Castillo J, Senaldi G et al. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood87(12), 5006–5015 (1996).
  • Villeval JL, Cohen-Solal K, Tulliez M et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood90(11), 4369–4383 (1997).
  • Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br. J. Haematol.139(3), 351–362 (2007).
  • Bussel JB, Schindler AM, Grossbard EB. R935788: a Phase II, single center, open label, efficacy and safety, ascending dose, pilot study for the treatment of adult immune thrombocytopenic purpura (ITP). Blood110(11) (2007) (Abstract 1310).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.